Tempest Therapeutics Stock Performance
| TPST Stock | USD 2.31 0.02 0.86% |
The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tempest Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tempest Therapeutics is expected to be smaller as well. At this point, Tempest Therapeutics has a negative expected return of -1.82%. Please make sure to validate Tempest Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Tempest Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (0.86) | Five Day Return 4.52 | Year To Date Return (21.69) | Ten Year Return (99.80) | All Time Return (99.86) |
Last Split Factor 1:13 | Dividend Date 2018-12-10 | Last Split Date 2025-04-09 |
1 | Crude Oil Falls Over 2 Lowes Shares Gain After Q3 Results | 11/19/2025 |
2 | Acquisition by Justin Trojanowski of 30000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3 | 11/21/2025 |
3 | Tempest Announces Closing of Up To 8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Und... | 11/26/2025 |
4 | Acquisition by Woiwode Thomas of 3500 shares of Tempest Therapeutics subject to Rule 16b-3 | 11/28/2025 |
5 | Will Tempest Therapeutics Inc. stock beat EPS estimates - July 2025 Weekly Recap Weekly High Potential Stock Alerts - bolumsonucanavari.com | 12/22/2025 |
6 | Tempest Therapeutics receives Nasdaq notice for annual meeting compliance - Investing.com | 01/09/2026 |
7 | Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders | 01/20/2026 |
8 | Acquisition by Pellizzari Christine A of 1230 shares of Tempest Therapeutics at 2.94 subject to Rule 16b-3 | 01/27/2026 |
9 | Insider Trading | 02/03/2026 |
10 | 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga | 02/05/2026 |
| Begin Period Cash Flow | 39.7 M | |
| Total Cashflows From Investing Activities | -435 K |
Tempest Therapeutics Relative Risk vs. Return Landscape
If you would invest 938.00 in Tempest Therapeutics on November 15, 2025 and sell it today you would lose (707.00) from holding Tempest Therapeutics or give up 75.37% of portfolio value over 90 days. Tempest Therapeutics is currently does not generate positive expected returns and assumes 8.879% risk (volatility on return distribution) over the 90 days horizon. In different words, 79% of stocks are less volatile than Tempest, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tempest Therapeutics Target Price Odds to finish over Current Price
The tendency of Tempest Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.31 | 90 days | 2.31 | about 74.55 |
Based on a normal probability distribution, the odds of Tempest Therapeutics to move above the current price in 90 days from now is about 74.55 (This Tempest Therapeutics probability density function shows the probability of Tempest Stock to fall within a particular range of prices over 90 days) .
Tempest Therapeutics Price Density |
| Price |
Predictive Modules for Tempest Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tempest Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tempest Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Tempest Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tempest Therapeutics is not an exception. The market had few large corrections towards the Tempest Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tempest Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tempest Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.73 | |
β | Beta against Dow Jones | 0.83 | |
σ | Overall volatility | 2.12 | |
Ir | Information ratio | -0.2 |
Tempest Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tempest Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tempest Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga |
Tempest Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tempest Stock often depends not only on the future outlook of the current and potential Tempest Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tempest Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.9 M | |
| Cash And Short Term Investments | 30.3 M |
Tempest Therapeutics Fundamentals Growth
Tempest Stock prices reflect investors' perceptions of the future prospects and financial health of Tempest Therapeutics, and Tempest Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tempest Stock performance.
| Return On Equity | -4.05 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 12.47 M | ||||
| Shares Outstanding | 4.93 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 1.82 X | ||||
| EBITDA | (40.14 M) | ||||
| Net Income | (41.84 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 15.37 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.43 X | ||||
| Cash Flow From Operations | (33.03 M) | ||||
| Earnings Per Share | (9.73) X | ||||
| Market Capitalization | 11.48 M | ||||
| Total Asset | 41.49 M | ||||
| Retained Earnings | (207.11 M) | ||||
| Working Capital | 17.25 M | ||||
About Tempest Therapeutics Performance
Assessing Tempest Therapeutics' fundamental ratios provides investors with valuable insights into Tempest Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tempest Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.22) | |
| Return On Capital Employed | (1.77) | (1.68) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.97) | (2.07) |
Things to note about Tempest Therapeutics performance evaluation
Checking the ongoing alerts about Tempest Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tempest Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Thursdays Pre-Market Session - Benzinga |
- Analyzing Tempest Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tempest Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tempest Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tempest Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tempest Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tempest Therapeutics' stock. These opinions can provide insight into Tempest Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.